Sponsor

Universität Duisburg-Essen

Clinical research sponsor

Published trials30
Recruiting shown0
Roles2
SourceClinicalTrials.gov

Clinical trials

30 shown
Supportive Effects of Craniosacral Therapy for Women With Breast CancerNCT04319510 · lead sponsor · 2023-09-18
COMPLETED
LVRS Versus BLVR in Patients With Homogenous Emphysema, CLUB-HE TrialNCT04781582 · lead sponsor · 2021-06-08
UNKNOWN
Whole-body Hyperthermia for Moderate to Severe Depressive DisorderNCT03906149 · lead sponsor · 2019-07-01
COMPLETED
Effectiveness of Ear Acupuncture to Improve Insomnia in Women With Breast CancerNCT03874598 · lead sponsor · 2019-06-12
COMPLETED
Whole-body Hyperthermia for Mild to Moderate Depressive DisorderNCT03906175 · lead sponsor · 2019-06-11
COMPLETED
Yoga as a Supportive Therapy for Patients With HypertensionNCT02727140 · lead sponsor · 2016-05-01
COMPLETED
Mind-Body Medicine Day Care Clinic in Breast Cancer Patients Undergoing Endocrine TherapyNCT02669576 · lead sponsor · 2016-01-01
COMPLETED
Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)NCT02595840 · lead sponsor · 2015-11-25
TERMINATED
Yoga for Abdominal ObesityNCT02420145 · lead sponsor · 2015-04-01
COMPLETED
Preoperative Relaxation Training and Acupuncture to Minimize Perioperative Symptoms in Breast Cancer PatientsNCT02276404 · lead sponsor · 2014-11-01
COMPLETED
Effects of Fasting on Self EfficacyNCT02113111 · lead sponsor · 2014-04-01
COMPLETED
Comprehensive Lifestyle Modification for Patients With Hypertension and Metabolic Syndrome: a Multicenter Randomized Controlled TrialNCT02099968 · lead sponsor · 2014-04-01
COMPLETED
Effects of Yoga on Menopausal Symptoms in Women With Breast CancerNCT01908270 · lead sponsor · 2013-08-01
COMPLETED
Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLCNCT01742767 · lead sponsor · 2012-11-01
UNKNOWN
Iyengar Yoga for Chemotherapy-induced Fatigue in Breast Cancer PatientsNCT01686737 · lead sponsor · 2012-11-01
WITHDRAWN
Effects of an Integrative Day-care Clinic Program for Breast Cancer Patients During ChemotherapyNCT03868865 · lead sponsor · 2012-08-07
COMPLETED
Complementary and Integrative Therapy for Diabetic NeuropathyNCT01296308 · lead sponsor · 2011-03-01
COMPLETED
Effectiveness of a Digital Health Application for Multiple Sclerosis (Levidex)NCT06090305 · collaborator · 2023-11-20
COMPLETED
Structured Psychoeducation for Unemployed Adolescents With Extreme Obesity in a Multicenter Observational Study Focusing on FeasibilityNCT02607995 · collaborator · 2015-05-28
COMPLETED
Weight Loss Surgery in Adolescents With Extreme ObesityNCT02062164 · collaborator · 2013-11-01
ACTIVE_NOT_RECRUITING
Low-level Intervention for Adolescents With Extreme ObesityNCT01703273 · collaborator · 2012-07-01
COMPLETED
Identification and Characterization of Youth With Extreme ObesityNCT01625325 · collaborator · 2012-07-01
COMPLETED
Course of Obesity and Extreme Obesity in AdolescentsNCT01662271 · collaborator · 2012-07-01
COMPLETED
Economic Aspects of Extreme Obesity in AdolescentNCT01632098 · collaborator · 2012-07-01
COMPLETED
The Impact of Psychological Interventions on Psychometric and Immunological Measures in Patients With Major DepressionNCT01464463 · collaborator · 2011-08-01
COMPLETED
Bupropion for the Treatment of Apathy in Alzheimer's DementiaNCT01047254 · collaborator · 2010-01-01
COMPLETED
Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode SchizophreniaNCT00159120 · collaborator · 2001-11-01
COMPLETED
Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode SchizophreniaNCT00159133 · collaborator · 2001-11-01
COMPLETED
One Year Drug Treatment in First-Episode SchizophreniaNCT00159081 · collaborator · 2000-11-01
COMPLETED
Optimization of Acute Treatment in First Episode SchizophreniaNCT00157378 · collaborator · 2000-11-01
UNKNOWN

Sponsor roles

lead sponsor17
collaborator13

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.